Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804, in patients with moderately to severely active ulcerative colitis or Crohn's disease that is refractory to systemic therapies

Johnson & Johnson's announcement of Phase 2b data for JNJ-4804 is significant as it evaluates a potential treatment for difficult cases of ulcerative colitis and Crohn's disease.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

US General Caine says Iran has fired at commercial vessels nine times and seized two container ships since the ceasefire was announced; Iran continues to launch attacks on its neighbouring countries

Alphabet (GOOGL) to offer Canadian Dollar notes in four-parter

Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804, in patients with moderately to severely active ulcerative colitis or Crohn's disease that is refractory to systemic therapies

Alphabet (GOOGL) set to raise at least EUR 9bln in its record Euro bond issuance

US DoW Secretary Hegseth says Project Freedom is separate from Epic Fury, it is temporary; US aims to protect shipping from Iranian aggression. We are not looking for a fight, Iran is the clear aggressor

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Positive data could bolster JNJ's standing in the pharmaceutical sector and attract investor interest, enhancing the outlook for future revenues. Investors will be watching closely for market reactions based on efficacy and safety profiles of the treatment.

Related headlines

The whole workspace, free to try.

Try it free